microRNA(miRNA)能够抑制致病基因转录表达,是潜在的治疗恶性肿瘤的基因武器。如何在体内把miRNA定向导入目标细胞是应用miRNA治疗恶性肿瘤的关键问题。本课题拟结合具有细胞导向功能的单链片段抗体(ScFv)技术和RNAi技术,研制抗Her2受体的ScFv与荷正电多肽的融合蛋白,以携带抗肿瘤miRNA表达载体选择性导入Her2阳性的乳腺癌细胞。同时,用Her2 ScFv修饰能浓缩基因物质的脂质体,制成具有定向结合Her2受体和携带siRNA双向功能的免疫脂质载体。分别在体外乳腺癌细胞培养,以及荷瘤鼠和肝转移模型中检测上述非病毒载体导向工具输送miRNA表达载体的功能和抗瘤效应。开发基于导向性miRNA 的新型基因抗癌药物,同时为miRNA靶向导入目标细胞的研发提供新思路。
{{i.achievement_title}}
数据更新时间:2023-05-31
Efficient photocatalytic degradation of organic dyes and reaction mechanism with Ag2CO3/Bi2O2CO3 photocatalyst under visible light irradiation
Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling
An alternative conformation of human TrpRS suggests a role of zinc in activating non-enzymatic function
Baicalin provides neuroprotection in traumatic brain injury mice model through Akt/Nrf2 pathway
IRE1-RACK1 axis orchestrates ER stress preconditioning-elicited cytoprotection from ischemia/reperfusion injury in liver
miRNA在乳腺癌抗HER-2靶向治疗耐药中对HER-2蛋白表达的调控机制
基于细胞衰老表型的超声靶向探针评估Her-2阳性乳腺癌的靶向治疗后耐药
靶向乳腺癌干细胞导入mir-30a抑制乳腺癌转移的研究
基因修饰的内皮祖细胞靶向治疗HER-2阳性肿瘤的实验研究